Shanghai Junshi Biosciences Co., Ltd. Class A
16.54
HKD
-0.66
(-3.84%)
ISIN
CNE100003FF7
Return %
Stock
S&P 500
1Y
-37.25
14.20
3Y
-7.80
81.12
5Y
-60.34
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Cong Li
- Full Time Employees
- 2,903
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building 7 Shanghai SH China 200126
- IPO Date
- Dec 24, 2018
- Website
- junshipharma.com
- Similar Companies
- Business
- Shanghai Junshi Biosciences Co., Ltd. (688180.SS) is an innovation-driven biopharmaceutical company focused on the discovery, development, clinical research, and commercialization of innovative therapeutics targeting malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases. Founded in 2012 and headquartered in Shanghai, People's Republic of China, the company operates primarily in China with global reach through manufacturing bases in Suzhou and Shanghai, innovation centers in Shanghai, Suzhou, and the United States, and commercialization partnerships spanning North America, Europe, Southeast Asia, the Middle East, and other regions. Its core products include toripalimab (TUOYI®/LOQTORZI®, an anti-PD-1 monoclonal antibody approved for 12 indications in China such as melanoma, nasopharyngeal carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, small cell lung cancer, and triple-negative breast cancer, and internationally in the US, EU, UK, Australia, Singapore, and others); adalimumab (JUNMAIKANG®, a TNF-α biosimilar for rheumatoid arthritis); ongericimab (JUNSHIDA®, a PCSK9 inhibitor for hypercholesterolemia and mixed dyslipidemia, recently approved for statin-intolerant patients); deuremidevir hydrobromide (MINDEWEI®, VV116, an oral antiviral for COVID-19); etesevimab (a SARS-CoV-2 monoclonal antibody); and an extensive R&D pipeline encompassing antibody-drug conjugates (e.g., JS108 targeting Trop2, JS212 EGFR×HER3 ADC, JS107 Claudin18.2 ADC), bispecific antibodies (e.g., PD-1×IL-2, PD-1×VEGF, CD3+CD20), small molecules (e.g., JS105 PI3K-α, JS116 KRAS), fusion proteins, nucleic acid drugs, and others like tifcemalimab (BTLA), JS005 (IL-17A), and JS401 (ANGPTL3 siRNA). Recent developments include multiple supplemental new drug application approvals for toripalimab in 2024, such as first-line treatments for extensive-stage small cell lung cancer and triple-negative breast cancer, perioperative non-small cell lung cancer, and renal cell carcinoma; ongericimab's two sNDAs approved by China's NMPA in 2025 for statin-intolerant patients; commercialization partnerships like the 2025 distribution and marketing agreement with LEO Pharma for toripalimab (LOQTORZI®) in Europe, a joint venture with Rxilient Biotech for Southeast Asia, and collaborations with Coherus BioSciences (expanded to TIGIT), Dr. Reddy’s (21 countries), and Hikma (Middle East/North Africa); approvals in new markets including UAE, Kuwait, Pakistan, Canada, Hong Kong SAR, India, and others for toripalimab; construction of the Suzhou Wujiang Production Base; and robust financial growth with 2024 revenue of RMB1.948 billion (up 30% year-over-year) and first-half 2025 revenue of RMB1.168 billion.
Company News
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis